Niclosamide vs Methylene Blue for Spike Protein Disease (2025)
Spike protein disease refers to the pathological effects of the SARS-CoV-2 spike protein, including acute infection via ACE2 receptor binding, syncytia formation, and chronic sequelae like oxidative stress, inflammation, mitochondrial dysfunction, and cytokine storms. Both niclosamide (an FDA-approved anthelmintic) and methylene blue (an FDA-approved redox agent) are repurposed drugs with antiviral properties against SARS-CoV-2, including variants like Omicron. They target different aspects of spike-mediated pathology: methylene blue excels in direct spike inhibition and toxicity mitigation, while niclosamide focuses on viral entry and clearance. Below is a structured comparison based on preclinical and clinical data as of September 2025. Primary Mechanisms Niclosamide : Acts as a protonophore to neutralize endosomal pH, blocking viral internalization and replication. Inhibits TMEM16 proteins, preventing spike-induced syncytia formation and platelet activation. Targets CD147 receptor t...